GlassScriptPhysician profile
Purva Sharma
NPI 1912285560
$2,669.77
in general payments reported to CMS, 2019-2025
19 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.29 · 2022: $491 · 2023: $71.72 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,965 · Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,965.00 |
| Food and Beverage | $201.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,965.00 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $130.00 | 2025 | Voyxact |
| Novartis Pharmaceuticals Corporation | $104.34 | 2022 | |
| Janssen Biotech, INC. | $88.27 | 2022 | |
| Pfizer INC. | $43.73 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $39.58 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $39.13 | 2022 | |
| Foundation Medicine, INC. | $36.34 | 2022 | |
| Genmab U.S., INC. | $26.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.33 | 2022 | |
| Taiho Oncology, INC. | $25.50 | 2022 | |
| Amgen INC. | $24.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.57 | 2022 | |
| Octapharma USA, INC. | $20.08 | 2022 | |
| Beigene USA, INC. | $19.14 | 2023 | Brukinsa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.33 | 2023 | Enhertu |
| Global Blood Therapeutics, INC. | $14.95 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.86 | 2022 | |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purva Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.